ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 156 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $989,159 | +271.9% | 88,555 | +612.5% | 0.00% | – |
| Q2 2023 | $265,959 | -92.9% | 12,428 | -86.5% | 0.00% | – |
| Q1 2023 | $3,736,090 | +8.4% | 92,386 | +24.7% | 0.00% | -100.0% |
| Q4 2022 | $3,446,806 | -33.9% | 74,093 | -26.4% | 0.00% | 0.0% |
| Q3 2022 | $5,218,000 | +93.3% | 100,608 | +76.2% | 0.00% | – |
| Q2 2022 | $2,699,000 | -10.7% | 57,093 | +34.5% | 0.00% | – |
| Q1 2022 | $3,021,000 | -61.3% | 42,437 | -59.4% | 0.00% | – |
| Q4 2021 | $7,816,000 | +348.2% | 104,532 | +240.6% | 0.00% | – |
| Q3 2021 | $1,744,000 | +16.7% | 30,693 | -9.6% | 0.00% | – |
| Q2 2021 | $1,495,000 | -57.2% | 33,952 | -52.0% | 0.00% | – |
| Q1 2021 | $3,492,000 | -41.3% | 70,802 | -49.9% | 0.00% | – |
| Q4 2020 | $5,948,000 | +983.4% | 141,270 | +1077.2% | 0.00% | – |
| Q3 2020 | $549,000 | +54.2% | 12,000 | +69.1% | 0.00% | – |
| Q2 2020 | $356,000 | -72.4% | 7,097 | -71.7% | 0.00% | – |
| Q1 2020 | $1,288,000 | -74.1% | 25,039 | -68.9% | 0.00% | -100.0% |
| Q4 2019 | $4,980,000 | -46.4% | 80,600 | -47.9% | 0.00% | -33.3% |
| Q3 2019 | $9,296,000 | -80.0% | 154,737 | -71.9% | 0.00% | -50.0% |
| Q2 2019 | $46,511,000 | +870.0% | 551,214 | +998.0% | 0.01% | +200.0% |
| Q1 2019 | $4,795,000 | -19.4% | 50,200 | -40.2% | 0.00% | 0.0% |
| Q4 2018 | $5,950,000 | +31.1% | 84,000 | +58.2% | 0.00% | +100.0% |
| Q3 2018 | $4,538,000 | -37.6% | 53,100 | -15.4% | 0.00% | -66.7% |
| Q2 2018 | $7,277,000 | +129.8% | 62,793 | +60.4% | 0.00% | +200.0% |
| Q1 2018 | $3,166,000 | +433.9% | 39,136 | +287.5% | 0.00% | – |
| Q4 2017 | $593,000 | -55.2% | 10,100 | -64.3% | 0.00% | – |
| Q3 2017 | $1,325,000 | -68.7% | 28,300 | -76.0% | 0.00% | -100.0% |
| Q2 2017 | $4,239,000 | +155.8% | 117,815 | +119.0% | 0.00% | 0.0% |
| Q1 2017 | $1,657,000 | +240.9% | 53,800 | +271.0% | 0.00% | – |
| Q4 2016 | $486,000 | -37.2% | 14,500 | -50.2% | 0.00% | – |
| Q3 2016 | $774,000 | -38.9% | 29,100 | -49.3% | 0.00% | – |
| Q2 2016 | $1,266,000 | -70.2% | 57,400 | -60.3% | 0.00% | -100.0% |
| Q1 2016 | $4,243,000 | -38.5% | 144,495 | -30.9% | 0.00% | +50.0% |
| Q4 2015 | $6,900,000 | +162.9% | 208,969 | +187.7% | 0.00% | +100.0% |
| Q3 2015 | $2,625,000 | -22.5% | 72,640 | -3.5% | 0.00% | -50.0% |
| Q2 2015 | $3,389,000 | +35.8% | 75,306 | -7.6% | 0.00% | +100.0% |
| Q1 2015 | $2,496,000 | -65.6% | 81,518 | -42.8% | 0.00% | -50.0% |
| Q4 2014 | $7,248,000 | +126.7% | 142,527 | +76.4% | 0.00% | +100.0% |
| Q3 2014 | $3,197,000 | +30.6% | 80,781 | +42.2% | 0.00% | – |
| Q2 2014 | $2,447,000 | +1043.5% | 56,804 | +961.4% | 0.00% | – |
| Q1 2014 | $214,000 | – | 5,352 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |